ArticleFrontiers in oncology2026

AMACR and ZFPL1 serum biomarkers enhance precision in predicting postoperative prostate cancer outcomes.

Lin Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.